Tag: Herceptin

Articles

• Foods to eat and avoid during treatment with Herceptin
• Foods to eat and avoid for HER2+ patients and survivors
• HER2+ breast cancer characteristics

News

08/06/24

Apple flavonoid phloretin enhances anti-cancer effects of Herceptin

10/07/20

Differences in HER2 expression between tumors affects outcomes

05/01/16

Six-month delay in starting Herceptin linked to reduced survival

05/23/15

Sulforaphane inhibits HER2+ and triple negative breast cancer

07/22/12

Inflammation can contribute to resistance to Herceptin

05/13/12

A story of long-term stage IV HER2+ breast cancer survival

04/19/12

Green tea polyphenol EGCG slows development of tamoxifen resistance

12/13/11

Metformin improves survival of diabetic women with HER2+ BC

12/01/11

Herceptin + anthracycline chemo increases risk of cardiomyopathy

Studies

• Apple polyphenol phloretin inhibits type II glucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer Cite
  Chang H, Cheng T, Tu S, Liao P, Lee Y, Ho C, et al. Apple polyphenol phloretin inhibits type II glucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer. Food Science and Human Wellness. Tsinghua University Press; 2024; 10.26599/fshw.2024.9250251
• Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial Cite
  Kettana KM, El‑Haggar SM, Alm El-Din MA, El‑Afify DR. Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Medical Oncology. Springer Science and Business Media LLC; 2024; 41 10.1007/s12032-024-02426-1
• Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression Cite
  Franceschi BT, Bezerra PHA, Torqueti MR. Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01590-6
• Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Cite
  Masuda Y, Yamashita S, Nakayama Y, Shimizu R, Konishi M. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Biological and Pharmaceutical Bulletin. Pharmaceutical Society of Japan; 2024; 47:840-847 10.1248/bpb.b23-00802
• Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan Cite
  Haque R, Chen LH, Oestreicher N, Lalla D, Chlebowski RT. Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan. Breast Cancer: Targets and Therapy. Informa UK Limited; 2023; Volume 15:637-645 10.2147/bctt.s420061
• Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study Cite
  Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby SC, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study. BMJ. BMJ; 2023;:e074684 10.1136/bmj-2022-074684
• Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study Cite
  Shi Y, Qiu Z, Yu J, Li Z, Hua S, Chen Y, et al. Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11102-y
• Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy Cite
  Arinno A, Maneechote C, Khuanjing T, Prathumsap N, Chunchai T, Arunsak B, et al. Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2023; 1869:166618 10.1016/j.bbadis.2022.166618
• Estimating the incidence of breast cancer recurrence using administrative data Cite
  Habbous S, Barisic A, Homenauth E, Kandasamy S, Forster K, Eisen A, et al. Estimating the incidence of breast cancer recurrence using administrative data. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06812-z
• Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study Cite
  Liikanen JS, Leidenius M, Joensuu H, Meretoja TJ. Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study. Breast Care. S. Karger AG; 2022; 17:279-287 10.1159/000520793
• Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection Cite
  Shirmard LR, Shabani M, Moghadam AA, Zamani N, Ghanbari H, Salimi A. Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection. Cardiovascular Toxicology. Springer Science and Business Media LLC; 2022; 10.1007/s12012-022-09750-w
• Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice Cite
  Eekhoudt CR, Bortoluzzi T, Varghese SS, Cheung DYC, Christie S, Eastman S, et al. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice. Current Oncology. MDPI AG; 2022; 29:2941-2953 10.3390/curroncol29050241
• Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study Cite
  Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.01736
• Omega-9 fatty acids: potential roles in inflammation and cancer management Cite
  Farag MA, Gad MZ. Omega-9 fatty acids: potential roles in inflammation and cancer management. Journal of Genetic Engineering and Biotechnology. Springer Science and Business Media LLC; 2022; 20 10.1186/s43141-022-00329-0
• Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer Cite
  Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, et al. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer. Cancers. MDPI AG; 2022; 14:1015 10.3390/cancers14041015
• Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017 Cite
  Vo JB, Ramin C, Barac A, Berrington de Gonzalez A, Veiga L. Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06515-5
• The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study Cite
  Patel R, Lyne-Ethier J, Brogly S, Griffiths R, Hendry JM. The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1254626/v1
• A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer Cite
  Subramaniyan V, Fuloria S, Gupta G, Kumar DH, Sekar M, Sathasivam KV, et al. A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer. Chemico-Biological Interactions. Elsevier BV; 2022; 351:109735 10.1016/j.cbi.2021.109735
• Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors Cite
  Varghese SS, Johnston WJ, Eekhoudt CR, Keats MR, Jassal DS, Grandy SA. Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors. Current Oncology. MDPI AG; 2021; 28:4139-4156 10.3390/curroncol28050351
• Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1 Cite
  Woo J, Kim JB, Cho T, Yoo EH, Moon B, Kwon H, et al. Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1. PLOS ONE. Public Library of Science (PLoS); 2021; 16:e0257298 10.1371/journal.pone.0257298
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, et al. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology. Elsevier BV; 2021; 22:1139-1150 10.1016/s1470-2045(21)00288-6
• Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer Cite
  Nami B, Ghanaeian A, Black C, Wang Z. Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. Life. MDPI AG; 2021; 11:868 10.3390/life11090868
• Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial Cite
  Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, et al. Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-766187/v1
• Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial Cite
  Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, et al. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06253-0
• Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway Cite
  Kwon Y, Nam K, Kim S. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochemical Pharmacology. Elsevier BV; 2021;:114635 10.1016/j.bcp.2021.114635
• Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer Cite
  Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06192-w
• Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach Cite
  DuMond B, Patel V, Gross A, Fung A, Weber S. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. Journal of Oncology Pharmacy Practice. SAGE Publications; 2021;:107815522199971 10.1177/1078155221999712
• Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study Cite
  Abdel‐Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo‐Argüelles O, Amir E, et al. Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study. Journal of the American Heart Association. Ovid Technologies (Wolters Kluwer Health); 2021; 10.1161/jaha.119.018393
• FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer Cite
  Gao JJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, et al. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020;:clincanres.3474.2020 10.1158/1078-0432.ccr-20-3474
• Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018) Cite
  Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O, et al. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018). European Journal of Cancer. Elsevier BV; 2020; 141:209-217 10.1016/j.ejca.2020.10.012
• Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer Cite
  Dackus GMHE, Jóźwiak K, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, et al. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05978-8
• Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer Cite
  Abdel-Razeq H, Edaily S, Iweir S, Salam M, Saleh Y, Sughayer M, et al. Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05942-6
• Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study Cite
  Jacobse JN, Schaapveld M, Boekel NB, Hooning MJ, Jager A, Baaijens MHA, et al. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05930-w
• Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients Cite
  Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, et al. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3743-3752 10.1200/jco.20.00184
• Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database Cite
  Nahleh ZA, Elimimian EB, Elson LC, Hobbs B, Wei W, Blake CN. Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2020; 14:117822342094569 10.1177/1178223420945694
• Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2020; 23:259 10.4048/jbc.2020.23.e34
• The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice Cite
  Asselin CY, Lam A, Cheung DYC, Eekhoudt CR, Zhu A, Mittal I, et al. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice. The Journal of Nutrition. Oxford University Press (OUP); 2020; 150:2353-2363 10.1093/jn/nxaa144
• A Polyphenol-Rich Muscadine Grape Extract Inhibits HER + Breast Cancer and Protects Against Trastuzumab-Induced Cardiotoxicity Cite
  Mackert J, Gallagher P, Tallant E. A Polyphenol-Rich Muscadine Grape Extract Inhibits HER + Breast Cancer and Protects Against Trastuzumab-Induced Cardiotoxicity. Current Developments in Nutrition. Oxford University Press (OUP); 2020; 4:334-334 10.1093/cdn/nzaa044_033
• Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients Cite
  Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 182:333-343 10.1007/s10549-020-05703-5
• Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada Cite
  Rushton M, Lima I, Tuna M, Johnson C, Ivars J, Pritchard K, et al. Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 112:1222-1230 10.1093/jnci/djaa054
• Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session Cite
  Deken MM, Kijanka MM, Beltrán Hernández I, Slooter MD, de Bruijn HS, van Diest PJ, et al. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release. Elsevier BV; 2020; 323:269-281 10.1016/j.jconrel.2020.04.030
• Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study Cite
  Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 122:1747-1753 10.1038/s41416-020-0815-9
• Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study Cite
  Kaboré EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLOS Medicine. Public Library of Science (PLoS); 2019; 16:e1002989 10.1371/journal.pmed.1002989
• Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016) Cite
  Tang M, Schaffer A, Kiely BE, Daniels B, Simes RJ, Lee CK, et al. Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016). British Journal of Cancer. Springer Science and Business Media LLC; 2019; 121:904-911 10.1038/s41416-019-0612-5
• Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 Cite
  Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, et al. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:3425-3435 10.1200/jco.19.00443
• Prevalence and associated factors of weight gain after early breast cancer diagnosis Cite
  Tessomboon K, Chompoonuch S. Prevalence and associated factors of weight gain after early breast cancer diagnosis. Annals of Oncology. Elsevier BV; 2019; 30:vi137 10.1093/annonc/mdz343.090
• Abstract 296: Trastuzumab sensitizes HER2+ breast cancer to increase efficacy of chemotherapyin vitroandin vivo Cite
  Shah A, Jarrett A, Syed A, Yankeelov T, Sorace A. Abstract 296: Trastuzumab sensitizes HER2+ breast cancer to increase efficacy of chemotherapyin vitroandin vivo. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-296
• Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment Cite
  Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology. Springer Science and Business Media LLC; 2019; 42:815-828 10.1007/s13402-019-00464-w
• Abstract 1860: Muscadine grape extract prevents proliferation of trastuzumab-sensitive and -resistant HER2 positive breast cancer cells and has synergistic effects when combined with trastuzumab Cite
  Mackert J, Gallagher PE, Tallant EA. Abstract 1860: Muscadine grape extract prevents proliferation of trastuzumab-sensitive and -resistant HER2 positive breast cancer cells and has synergistic effects when combined with trastuzumab. Cancer Chemistry. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-1860
• Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer Cite
  Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2019; 73:2859-2868 10.1016/j.jacc.2019.03.495
• Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Cite
  von Minckwitz G, Huang C, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2019; 380:617-628 10.1056/nejmoa1814017
• Loss of HER2 after HER2-targeted treatment Cite
  Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:401-408 10.1007/s10549-019-05173-4
• Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy Cite
  Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, et al. Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy. Breast Care. S. Karger AG; 2019; 14:388-393 10.1159/000495186
• Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial) Cite
  Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, et al. Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p1-11-21
• Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy Cite
  Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology. Elsevier BV; 2018; 35:153-159 10.1016/j.cjca.2018.11.028
• A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study Cite
  Lidbrink E, Chmielowska E, Otremba B, Bouhlel A, Lauer S, Liste Hermoso M, et al. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:187-196 10.1007/s10549-018-5058-6
• Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy Cite
  Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, et al. Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy. The Oncologist. Wiley; 2018; 24:313-318 10.1634/theoncologist.2018-0213
• Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project Cite
  Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, et al. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project. British Journal of Cancer. Springer Science and Business Media LLC; 2018; 119:374-380 10.1038/s41416-018-0114-x
• Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients Cite
  Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC: Cardiovascular Imaging. Elsevier BV; 2018; 11:1084-1093 10.1016/j.jcmg.2018.06.005
• Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Cite
  Choi JY, Cho EY, Choi YJ, Lee JH, Jung SP, Cho KR, et al. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:181-188 10.1007/s10549-018-4809-8
• Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2 Cite
  Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3942-3948 10.1200/jco.2017.74.1165
• Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Cite
  Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2017; 18:e687-e694 10.1016/j.clbc.2017.11.012
• Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Cite
  Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2018; 18:e687-e694 10.1016/j.clbc.2017.11.012
• Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials Cite
  Yerushalmi R, Dong B, Chapman J, Goss P, Pollak M, Burnell M, et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Annals of Oncology. Elsevier BV; 2017; 28:1560-1568 10.1093/annonc/mdx152
• Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany Cite
  Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, et al. Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. The Oncologist. Wiley; 2017; 22:131-138 10.1634/theoncologist.2016-0193
• Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective Cite
  Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0172731 10.1371/journal.pone.0172731
• Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab Cite
  Blanchette P, Desautels D, Pond G, Bartlett J, Nofech-Mozes S, Yaffe M, et al. Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p6-09-30
• Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials Cite
  Hao S, Tian W, Gao B, Jiang Y, Zhang X, Zhang S, et al. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials. Oncotarget. Impact Journals, LLC; 2017; 8:19923-19933 10.18632/oncotarget.15252
• 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Cite
  Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. Elsevier BV; 2017; 389:1195-1205 10.1016/s0140-6736(16)32616-2
• Induction of G2M Arrest by Flavokawain A, A Kava Chalcone, Increases the Responsiveness of HER2 Overexpressing Breast Cancer Cells to Herceptin Cite
  Jandial DD, Krill LS, Chen L, Wu C, Ke Y, Xie J, et al. Induction of G2M Arrest by Flavokawain A, A Kava Chalcone, Increases the Responsiveness of HER2 Overexpressing Breast Cancer Cells to Herceptin. MDPI AG; 2017; 10.20944/preprints201701.0098.v1
• Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity Cite
  Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 35:870-877 10.1200/jco.2016.68.7830
• Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer Cite
  Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. JAMA. American Medical Association (AMA); 2017; 317:37 10.1001/jama.2016.18305
• Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer Cite
  Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:487-493 10.1016/j.clbc.2016.07.013
• Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis Cite
  Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:3157-3165 10.1200/jco.2016.67.4846
• The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Cite
  van Ramshorst MS, van der Heiden-van der Loo M, Dackus GMHE, Linn SC, Sonke GS. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 158:361-371 10.1007/s10549-016-3878-9
• Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer Cite
  Parkinson B, Viney R, Haas M, Goodall S, Srasuebkul P, Pearson S. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer. PharmacoEconomics. Springer Science and Business Media LLC; 2016; 34:1039-1050 10.1007/s40273-016-0411-2
• Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer Cite
  Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, et al. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:145-156 10.1007/s10549-016-3790-3
• Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab Cite
  Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, et al. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. American Medical Association (AMA); 2016; 2:1040 10.1001/jamaoncol.2016.0339
• Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study Cite
  Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2239-2246 10.1200/jco.2015.65.1505
• Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer Cite
  Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2003-2009 10.1200/jco.2015.65.8716
• A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer Cite
  Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, et al. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2016; 46:407-414 10.1093/jjco/hyw013
• Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database Cite
  Tseng YD, Uno H, Hughes ME, Niland JC, Wong Y, Theriault R, et al. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2015; 93:622-630 10.1016/j.ijrobp.2015.07.006
• Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab Cite
  Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, et al. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. The Breast. Elsevier BV; 2016; 25:22-26 10.1016/j.breast.2015.11.006
• Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer Cite
  Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:29 10.1001/jamaoncol.2015.3709
• Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry Cite
  Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology. Elsevier BV; 2016; 27:480-487 10.1093/annonc/mdv611
• Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474) Cite
  Mason JK, Fu M, Chen J, Thompson LU. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). The Journal of Nutritional Biochemistry. Elsevier BV; 2015; 26:16-23 10.1016/j.jnutbio.2014.08.001
• Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells Cite
  Ravacci GR, Brentani MM, Tortelli TC, Torrinhas RSMM, Santos JR, Logullo AF, et al. Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells. BioMed Research International. Hindawi Limited; 2015; 2015:1-13 10.1155/2015/838652
• The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study Cite
  Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, et al. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv301 10.1093/jnci/djv301
• Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab Cite
  Cao L, Cai G, Chang C, Yang Z, Feng Y, Yu X, et al. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab. Oncotarget. Impact Journals, LLC; 2015; 7:1042-1054 10.18632/oncotarget.6053
• Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab Cite
  Sharieh EA, Awidi AS, Ahram M, Zihlif MA. Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab. Gene. Elsevier BV; 2016; 575:415-420 10.1016/j.gene.2015.09.019
• The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer Cite
  Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, et al. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0136731 10.1371/journal.pone.0136731
• Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis Cite
  Cook MT, Liang Y, Goyette S, Mafuvadze B, Besch-Williford C, Hyder S. Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis. Tumor Biology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-4159
• Abstract 913: Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer. Cite
  Burnett J, Korkaya H, Newman B, Conley S, Connarn J, Sun L, et al. Abstract 913: Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer.. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2013; 10.1158/1538-7445.am2013-913
• Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy Cite
  Strasser-Weippl K, Horick N, Smith IE, O’Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0568-1
• Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment? Cite
  Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, et al. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?. Clinical Breast Cancer. Elsevier BV; 2015; 15:277-284 10.1016/j.clbc.2014.12.012
• Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo Cite
  LIU W, XU J, LIU Y, YU X, TANG X, WANG Z, et al. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Molecular Medicine Reports. Spandidos Publications; 2014; 10:1921-1926 10.3892/mmr.2014.2414
• Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice Cite
  Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A, et al. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice. The Breast. Elsevier BV; 2014; 23:573-578 10.1016/j.breast.2014.05.022
• Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Cite
  Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet Oncology. Elsevier BV; 2014; 15:640-647 10.1016/s1470-2045(14)70080-4
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Cite
  André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. Elsevier BV; 2014; 15:580-591 10.1016/s1470-2045(14)70138-x
• Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer Cite
  Gagliato DdM, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, et al. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014; 32:735-744 10.1200/jco.2013.49.7693
• Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Cite
  Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. Wiley; 2013; 119:2447-2454 10.1002/cncr.28051
• Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer Cite
  Kim M, Allen P, Gonzalez-Angulo A, Woodward W, Meric-Bernstam F, Buzdar A, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology. Elsevier BV; 2013; 24:1999-2004 10.1093/annonc/mdt131
• AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007 Cite
  Valina-Toth AL, Zavodnik T, Seicean S, Plana J, Marwick T. AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007. Journal of the American College of Cardiology. Elsevier BV; 2013; 61:E580 10.1016/s0735-1097(13)60580-x
• Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab Cite
  Olson E, Abdel-Rasoul M, Maly J, Wu C, Lin N, Shapiro C. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Annals of Oncology. Elsevier BV; 2013; 24:1526-1533 10.1093/annonc/mdt036
• 3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells Cite
  Ahmad A, Ali S, Ahmed A, Ali AS, Raz A, Sakr WA, et al. 3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e54657 10.1371/journal.pone.0054657
• Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer Cite
  Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2012; 60:2504-2512 10.1016/j.jacc.2012.07.068
• Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Cite
  Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:563-570 10.1007/s12282-012-0424-4
• Docosahexanoic Acid Improves Chemotherapy Efficacy by Inducing CD95 Translocation to Lipid Rafts in ER− Breast Cancer Cells Cite
  Ewaschuk JB, Newell M, Field CJ. Docosahexanoic Acid Improves Chemotherapy Efficacy by Inducing CD95 Translocation to Lipid Rafts in ER− Breast Cancer Cells. Lipids. Wiley; 2012; 47:1019-1030 10.1007/s11745-012-3717-7
• Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study Cite
  Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:1293-1305 10.1093/jnci/djs317
• Pertuzumab: new hope for patients with HER2-positive breast cancer Cite
  Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini K, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology. Elsevier BV; 2013; 24:273-282 10.1093/annonc/mds328
• Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study Cite
  Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. The Breast. Elsevier BV; 2013; 22:301-308 10.1016/j.breast.2012.07.012
• Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer Cite
  Wang Q, Li S, Wang H, Xiao Y, Sahin O, Brady SW, et al. Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2012; 72:4417-4428 10.1158/0008-5472.can-12-1339-t
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Cite
  Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
• Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials Cite
  Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews. Elsevier BV; 2013; 39:44-50 10.1016/j.ctrv.2012.03.009
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Cite
  Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Elsevier BV; 2012; 379:633-640 10.1016/s0140-6736(11)61847-3
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) Cite
  Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®). Clinical and Translational Oncology. Springer Science and Business Media LLC; 2009; 11:455-459 10.1007/s12094-009-0384-0
• Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer Cite
  Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer. Journal of Cardiac Failure. Elsevier BV; 2012; 18:113-119 10.1016/j.cardfail.2011.10.015
• C-B2-01: Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network Cite
  Bowles EA, Wellman R, Delate T, Allen L, Feigelson HS, Yood MU, et al. C-B2-01: Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network. Clinical Medicine & Research. Marshfield Clinic Research Foundation; 2011; 9:148-148 10.3121/cmr.2011.1020.c-b2-01
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer Cite
  Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1273-1283 10.1056/nejmoa0910383
• Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cite
  Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. Wiley; 2011; 118:2385-2393 10.1002/cncr.26555
• Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. Cite
  Takita C, Reis IM, Miao F, LaFave KE, Gunaseelan V, Hurley J, et al. Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:112-112 10.1200/jco.2011.29.27_suppl.112
• Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions Cite
  Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. Informa UK Limited; 2011; 10:2959-2966 10.4161/cc.10.17.16359
• Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation Cite
  Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 128:899-906 10.1007/s10549-011-1495-1
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Cite
  Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology. Elsevier BV; 2011; 12:236-244 10.1016/s1470-2045(11)70033-x
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Cite
  Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. Wiley; 2011; 13:1-10 10.1093/eurjhf/hfq213
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Cite
  von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:145-156 10.1007/s10549-010-1228-x
• Impact of BMI on clinical outcome of HER2-positive breast cancer. Cite
  Parolin V, Fiorio E, Mercanti A, Riolfi M, Cetto GL, Surmacz E, et al. Impact of BMI on clinical outcome of HER2-positive breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1130-1130 10.1200/jco.2010.28.15_suppl.1130
• Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography. Cite
  Maurea N, De Lorenzo C, Coppola C, Ragone G, Di Pietro E, Schiattarella G, et al. Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11096-e11096 10.1200/jco.2010.28.15_suppl.e11096
• The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Cite
  Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:355-364 10.1007/s10549-010-0924-x
• The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer Cite
  Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. Wiley; 2010; 116:791-798 10.1002/cncr.24835
• Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Cite
  Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals of Oncology. Elsevier BV; 2010; 21:1254-1261 10.1093/annonc/mdp427
• Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells Cite
  Chang CJ, Chiu JH, Tseng LM, Chang CH, Chien TM, Wu CW, et al. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. European Journal of Clinical Investigation. Wiley; 2006; 36:588-596 10.1111/j.1365-2362.2006.01676.x
• HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail» Cite
  Menéndez JA, Vázquez-Martín A, Ropero S, Colomer R, Lupu R, Trueta J. HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail». Clinical and Translational Oncology. Springer Science and Business Media LLC; 2006; 8:812-820 10.1007/s12094-006-0137-2
• Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells Cite
  Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells. BMC Cancer. Springer Science and Business Media LLC; 2007; 7 10.1186/1471-2407-7-80
• Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification Cite
  Menendez J, Vellon L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification. Annals of Oncology. Elsevier BV; 2005; 16:359-371 10.1093/annonc/mdi090